Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
IPSC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $3.70
Previous CloseN/A
Volume712.78K
Average Volume (3M)599.13K
Market Cap
$45.62M
Enterprise Value-$49.67M
Total Cash (Recent Filing)$47.32M
Total Debt (Recent Filing)$48.17M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
May 08, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding86,045,040
10 Day Avg. Volume768,274
30 Day Avg. Volume599,135
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.79
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.60
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$4.80Price Target Upside788.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Century Therapeutics News
PremiumCompany Announcements
Century Therapeutics Reports 2024 Financial Results and Strategic Updates
PremiumCompany Announcements
Century Therapeutics Re-prioritizes Pipeline for Key Programs
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient in Century's Phase 1 (CALiPSO-1) trial in autoimmune diseases was enrolled, and five sites in the U.S. are actively screening patients.
Financial StabilityCentury expects its end-2024 cash position to provide an operational runway into 4Q26, which should be sufficient to generate meaningful clinical data for CNTY-101 in the autoimmune setting.
Technology AdvancementsCentury’s Allo-Evasion platform contains the most robust number of genetic edits for preventing host immune cell rejection.
Bears Say
Discontinuation Of ProgramsCentury announced the discontinuation of its lead program, CNTY-101 in B cell lymphomas due to the emerging clinical data not meeting the company’s threshold to be considered transformational.
Early Stage PipelineThe newly disclosed preclinical pipeline of CD19- and CD19/CD22-targeted αβ-CAR-iT cells, while promising, are considered too early to significantly impact Century's investment thesis.
Reduction In Price TargetThe removal of CNTY-101 applications in diffuse large B cell lymphoma and follicular lymphoma leads to a reduction in the 12-month price target from $5 to $2 per share.
---
Ownership Overview
3.70% Insiders
6.00% Mutual Funds
23.52% Other Institutional Investors
61.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.34 and its highest was $3.70 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $45.62M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Mar 19, 2025. The company reported -$0.41 earnings per share for the quarter, the consensus estimate of -$0.41 by $0.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is >-0.01.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 86,045,040 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.41 in its last earnings report, expectations of -$0.41. Following the earnings report the stock price went down -5.172%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
---
Century Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.80 (788.89% Upside)
$4.80 (788.89% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $33.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.09%
12-Months-Change
Fundamentals
Return on Equity
-73.14%
Trailing 12-Months
Asset Growth
-2.07%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
---
IPSC Stock 12 Month Forecast
Average Price Target
$4.80
▲(788.89% Upside)
Technical Analysis
Best Analysts Covering IPSC
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-43.09%
reiterated a buy rating 2 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -43.09% per trade.
---